Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal Post author:Sam Post published:November 19, 2017 Post category:BioPharma Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace You Might Also Like Medtronic EVP & RTG President To Speak At Cowen and Company Healthcare Conference February 26, 2017 A Look at the Types of Jobs Amgen's Promise to Will Bring February 2, 2017 Integer CEO Steps Down March 29, 2017
